VEGF inhibitors in brain tumors

Area of Science:

• Oncology
• Cancer Biology
• Vascular Biology

Background:

• Glioblastomas are characterized by significant vascularity.
• Angiogenesis, the formation of new blood vessels, is a key process in glioblastoma growth.
• Targeting angiogenesis has emerged as a potential therapeutic strategy for glioblastomas.

Purpose of the Study:

• To review current therapeutic strategies targeting angiogenesis in glioblastomas.
• To highlight the limitations and inevitable treatment failure observed.
• To emphasize the need for further research into resistance mechanisms and novel therapeutic targets.

Main Methods:

• Review of preclinical and clinical investigations.
• Analysis of therapeutic agents targeting vascular endothelial growth factor (VEGF) and its pathways.
• Examination of immunomodulatory agents and soluble decoy VEGF receptors.

Main Results:

• Various anti-angiogenic agents, including anti-VEGF antibodies and tyrosine kinase inhibitors, are under investigation.
• Despite initial promise, current anti-angiogenic therapies for glioblastoma inevitably lead to treatment failure.
• Tumor resistance to these therapies is a significant clinical challenge.

Conclusions:

• While targeting angiogenesis is a rational approach for glioblastomas, current treatments are not curative.
• Understanding the mechanisms underlying tumor resistance is critical for developing more effective therapies.
• Identification of alternative therapeutic targets that mediate angiogenesis is essential for future treatment strategies.